Trial of Pirfenidone to Prevent Progression in Chronic Kidney Disease
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Kidney disease is a global health problem, affecting more than 10% of the world's population
and more than half of adults over 70 years of age in the United States. Persons with kidney
disease are at higher risk for cardiovascular disease, heart failure, physical function
decline, and mortality. Kidney scarring is a dominant factor in the development of kidney
disease. Our group has evaluated several tests to determine the severity of scarring without
requiring kidney biopsies, using MRI imaging scans and evaluating markers of scarring that we
can measure in the urine. In this study we will use these measures to evaluate pirfenidone as
a promising potential new treatment for patients with kidney disease.
Phase:
Phase 2
Details
Lead Sponsor:
Veterans Medical Research Foundation
Collaborators:
Genentech, Inc. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) San Diego Veterans Healthcare System University of California, San Diego University of California, San Francisco